Synlogic’s pipeline is fueled by its Synthetic Biotic platform, which applies precision engineering to well-characterized probiotics. This creates GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for diseases such as PKU and HCU, both inborn errors of metabolism, as well as others in which the disease–specific metabolites transit through the GI tract, providing validated targets for these Synthetic Biotics.

Advancing a New Class of Biotherapeutics

Exploratory

Preclinical

IND-Enabling
Studies

Phase 1

Phase 2

Phase 3

Metabolic

Phenylketonuria (PKU)

Homocystinuria (HCU)

SYNB1934         RPDD        US - ODD          EU - OD    

SYNB1353       RPDD     US - ODD              FT                                                       

Enteric Hyperoxaluria

Gout

SYNB8802

SYNB2081

Immunology

Inflammatory Bowel Disease (IBD)

.

IBD Program – Single Target

.

 

RPDD = Rare Pediatric Disease Designation granted by FDA
EU – OD = Orphan Designation granted by EMA
US – ODD = Orphan Drug Designation granted by FDA
FT = Fast Track granted by FDA

Advancing a New Class of Biotherapeutics

Late-Stage Drug Candidates Focused on Rare Metabolic Diseases, PKU & HCU

PRE – 
CLINICAL

IND ENABLING

PHASE 1

PHASE 2

PHASE 3

Registration

labafenogene marselecobac (SYNB1934)

Phenylketonuria (PKU)

     RPDD                   FT                 ODD - US           OD - EU    

Labafenogene marselocebac

Phenylketonuria (PKU)

(SYNB1934)

 RPDD         US - ODD           EU - OD    

SYNB1353

Classical Homocystinuria (HCU)

     RPDD                   FT                 ODD - US  

SYNB8802

Enteric Hyperoxaluria

SYNB2081

Gout

Undisclosed

Cystinuria

Undisclosed

Inflammatory Bowel Disease (IBD)

RPDD = Rare Pediatric Disease Designation granted by FDA
FT = Fast Track granted by FDA
ODD – US = Orphan Drug Designation granted by FDA
OD – EU = Orphan Designation granted by EMA

Advancing a New Class of Biotherapeutics

Late-Stage Drug Candidates Focusedon Rare Metabolic Diseases, PKU & HCU

PRE – 
CLINICAL

IND ENABLING

PHASE 1

PHASE 2

PHASE 3

Registration

labafenogene marselecobac (SYNB1934)

Phenylketonuria (PKU)
     RPDD                   FT                 ODD - US           OD - EU    

SYNB1353

Classical Homocystinuria (HCU)

     RPDD                   FT                 ODD -US  

PRE – 
CLINICAL

IND ENABLING

PHASE 1

PHASE 2

PHASE 3

Registration

SYNB8802

Enteric Hyperoxaluria

SYNB2081

Gout

Undisclosed

Cystinuria

Undisclosed

Inflammatory Bowel Disease (IBD)

RPDD = Rare Pediatric Disease Designation granted by FDA
FT = Fast Track granted by FDA
ODD – US = Orphan Drug Designation granted by FDA
OD – EU = Orphan Designation granted by EMA

“We set out to identify diseases where we could have a meaningful impact and demonstrate the power and potential of drugs based on synthetic biology, leading us to focus on rare metabolic diseases, as well as enteric hyperoxaluria as initial programs. Once we understood the underlying molecular biology behind these conditions, we could rapidly design Synthetic Biotics that could potentially provide new treatment options for patients”

— Aoife Brennan, MB, ChB, President and Chief Executive Officer

Phenylketonuria (PKU)

Labafenogene marselecobac (SYNB1934) is an orally administered, non-systemically absorbed drug candidate being studied in the global, pivotal Phase 3 study, Synpheny-3, as a potential biotherapeutic for phenylketonuria (PKU). PKU is an inherited metabolic disease marked by an inability to break down the amino acid phenylalanine (Phe), which can be neurotoxic. Lifelong, consistent control of low Phe levels is required for avoiding the serious risks and complications of PKU. Treatment options for PKU are currently limited, with a majority of individuals with PKU in need of new medical treatment. Synlogic designed labafenogene marselecobac, an investigational medicine, to reduce levels of Phe in people with PKU by consuming Phe in the gastrointestinal (GI) tract, using genetic engineering of a well-characterized probiotic. Findings to date support the potential for an oral, efficacious, safe, convenient, and flexible treatment option for PKU. Labafenogene marselecobac has received Rare Pediatric Disease Designation, Fast Track designation, and Orphan Drug Designation by the FDA and Orphan Designation by the EMA.

Classical Homocystinuria (HCU)

SYNB1353 is a novel orally-administered, non-systemically absorbed drug candidate designed to consume methionine in the gastrointestinal tract thereby lowering homocysteine levels in patients with classical homocystinuria (HCU). HCU is an inherited disorder characterized by high levels of homocysteine and risks including thromboembolism, lens dislocation, skeletal abnormalities, developmental delay, and intellectual disability. Treatment options for HCU are currently limited due to safety, efficacy, and tolerability. Synlogic holds worldwide development and commercialization rights to SYNB1353, which is designed to consume methionine, a precursor to homocysteine, in the GI tract. The goal of treatment in HCU is to lower and control levels of total homocysteine (tHcy). SYNB1353 was granted Fast Track and Orphan Drug Designation by the FDA and is the first drug candidate developed through a research collaboration between Synlogic and Ginkgo Bioworks and the first investigational medicine developed on Ginkgo’s platform to enter the clinic. SYNB1353 has achieved proof of mechanism in a Phase 1 study using a dietary model of classical homocystinuria in healthy volunteers.

Enteric Hyperoxaluria

Enteric hyperoxaluria is a chronic, progressive disease characterized by high levels of urinary oxalate, the leading cause of recurrent kidney stones. Oxalate crystals can damage kidneys, potentially leading to damage that can include nephrocalcinosis, chronic kidney disease (CKD) and end-stage renal disease (ESRD). Enteric hyperoxaluria often occurs as a result of a primary insult to the bowel, such as inflammatory bowel disease or short bowel syndrome, or as a result of surgical procedures such as Roux-en-Y bariatric weight-loss surgery. There are currently no FDA approved treatment options. SYNB8802 is a drug candidate designed to consume dietary oxalate throughout the GI tract. SYNB8802 has demonstrated proof of concept through positive and clinically significant lowering of urinary oxalate in a Phase 1b study in patients with a history of gastric bypass surgery.

Gout

Gout is a complex form of inflammatory arthritis that occurs when extra uric acid in the body forms crystals in the joints. It includes symptoms such as intense joint pain, inflammation and redness, and limited range of motion in the affected joints. Current treatment options present limitations in both safety and efficacy, highlighting a need for new approaches. In addition, gout is a recognized risk factor in chronic kidney disease (CKD). SYNB2081 is a Synthetic Biotic designed to lower uric acid, as a potential treatment of gout. This is Synlogic’s second drug candidate developed through its partnership with Ginkgo Bioworks.

Cystinuria

Cystinuria is a genetic disease in which kidney stones consisting of an amino acid called cystine are formed in the kidney, ureter, and bladder. Normally, most cystine dissolves and returns to the bloodstream after entering the kidneys. People with cystinuria have inherited a genetic mutation that interferes with this process, increasing cystine the urine and leading to crystals or stone formation. Cystine stones tend to reoccur and are typically larger than other kidney stones, and may get stuck in the kidneys, ureters, or bladder. People with cystinuria often begin experiencing kidney stones in childhood. Synlogic is exploring the potential for a Synthetic Biotic approach to cystinuria.

Immunology

In June 2021, Synlogic began working with Roche on a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease. For more information click here.

 

Brendan St. Amant

Brendan joined Synlogic in 2021 as Vice President, Head of Legal. Prior to joining Synlogic, he was Vice President, Legal, and member of the leadership team at Ohana Biosciences and was senior counsel at Vertex Pharmaceuticals. Brendan was previously an associate and partner at the law firm of Donnelly, Conroy & Gelhaar, LLP, in Boston where he focused on commercial controversies and government enforcement. Earlier in his legal career, Brendan served as a clerk for the U.S. District Court for the District of Connecticut and was an associate at the law firm of Goodwin Procter. He received his B.A. in History from Cornell University, J.D. from Harvard Law School, and his M.P.P from the Harvard Kennedy School. Brendan has served on several practice-related bar committees and on the executive committee of the Board of Trustees of the Massachusetts Continuing Legal Education corporation. 

Interested in receiving news and updates about our work in PKU & HCU?

Sign up to stay connected.

By clicking above, I agree that Synlogic may send me information about the company and its programs, and that I have read, understood, and agree to the collection and use of my information as described in Synlogic’s privacy policy.

I can unsubscribe at any time by emailing patients@synlogictx.com with “Unsubscribe”.